Navid Malik, head of life sciences research at Cenkos Securities, discusses M&A activity in the pharmaceutical sector and says firms are narrowing their businesses along strategic lines.
Activist investor William Ackman of Pershing Square Capital and Valeant Pharmaceuticals International are said to be pursuing a takeover of Allergan.
Discussing Bill Ackman's partnership with Valeant to pursue a takeover of Allergan, with CNBC contributor Herb Greenberg and CNBC's Meg Tirrell.
Sarepta Therapeutics CEO Chris Garabedian discusses the prospects for what he calls a "potential accelerated approval" for its Duchenne muscular dystrophy drug Eteplirsen.
Sarepta Therapeutics is developing a drug for Duchenne muscular dystrophy. Its CEO Chris Garabedian discusses challenges the drug Eteplirsen has faced before the FDA.
Reports over the weekend say Pfizer may have approached AstraZenaca a few months ago, but talks fizzled. CNBC's Meg Tirrell reports analysts say Pfizer has about $70 billion in cash.
CNBC's Meg Tirrell discusses unconfirmed reports that Pfizer approached British rival AstraZeneca about a potential $101 billion merger.
Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.
Americans used more health services and spent more on prescription drugs in 2013, reversing a recent trend.
Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.
Ian Read, Pfizer CEO, discusses the pricing and affordability of drugs in the U.S. Read also weighs in on insurance coverage under the Affordable Care Act.
CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.
Richard Pops, chairman & CEO of Alkermes, discusses Alkermes' new injectable drug for the treatment of schizophrenia. We have more psychiatry products in our pipeline, reveals Pops.
John Lechleiter, Chairman, President & CEO of Eli Lilly, discusses the company's growth plans as products come off patent and consumers move to generic drugs.
The U.K. and U.S. governments spent millions stockpiling a flu drug that is no better than paracetamol, according to a new report.
Ultragenyx is now up around 150 percent from its IPO price. Its CEO Dr. Emil Kakkis provides insight on the development of its drugs, and just how committed the company is to treating patients with the diseases its drugs treat.
Eli Lilly and Takeda Pharmaceutical were ordered to pay billions in damages over claims that they concealed cancer risks of its Actos diabetes drug.
Emilia Falcetti, Analyst, Japan Healthcare Equity Research at Cantor Fitzgerald, says Daiichi Sankyo's decision to sell its controlling stake in Ranbaxy will have a negative impact on its earnings.
In order to diversify its business, Ireland's Mallinckrodt is buying California-based Questcor Pharmaceuticals in a deal reaching $5.2 billion.
U.S. health advisers recommended approval of MannKind's inhaled diabetes drug, and said the treatment could help those wary of needles.